Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) Target Price at $62.67

by · The Cerbat Gem

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the sixteen analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $62.6667.

A number of analysts have recently issued reports on JANX shares. Truist Financial started coverage on shares of Janux Therapeutics in a report on Wednesday, September 10th. They issued a “buy” rating and a $100.00 price objective on the stock. Wolfe Research began coverage on Janux Therapeutics in a research note on Tuesday, November 18th. They issued a “peer perform” rating on the stock. HC Wainwright reduced their target price on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. Bank of America dropped their target price on shares of Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating on the stock in a report on Tuesday, December 2nd. Finally, UBS Group reaffirmed a “buy” rating and set a $57.00 price target on shares of Janux Therapeutics in a research note on Tuesday, December 2nd.

View Our Latest Stock Analysis on JANX

Insider Activity

In related news, insider Andrew Hollman Meyer sold 3,333 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $32.98, for a total value of $109,922.34. Following the sale, the insider owned 84,974 shares in the company, valued at approximately $2,802,442.52. This trade represents a 3.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last 90 days, insiders sold 23,331 shares of company stock worth $710,862. Insiders own 29.40% of the company’s stock.

Institutional Trading of Janux Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. RA Capital Management L.P. boosted its holdings in Janux Therapeutics by 7.9% in the first quarter. RA Capital Management L.P. now owns 11,189,693 shares of the company’s stock worth $302,122,000 after acquiring an additional 824,041 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Janux Therapeutics by 19.4% in the first quarter. Adage Capital Partners GP L.L.C. now owns 3,654,574 shares of the company’s stock worth $98,673,000 after purchasing an additional 592,824 shares during the period. Orbimed Advisors LLC grew its position in shares of Janux Therapeutics by 45.9% during the third quarter. Orbimed Advisors LLC now owns 1,766,100 shares of the company’s stock worth $43,163,000 after purchasing an additional 555,800 shares in the last quarter. First Light Asset Management LLC increased its holdings in Janux Therapeutics by 110.0% in the 1st quarter. First Light Asset Management LLC now owns 658,824 shares of the company’s stock valued at $17,788,000 after acquiring an additional 345,042 shares during the last quarter. Finally, MPM Bioimpact LLC increased its stake in Janux Therapeutics by 146.6% in the 1st quarter. MPM Bioimpact LLC now owns 567,193 shares of the company’s stock worth $15,314,000 after acquiring an additional 337,193 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Trading Down 1.2%

Shares of NASDAQ:JANX opened at $15.12 on Friday. Janux Therapeutics has a 1-year low of $14.85 and a 1-year high of $63.00. The business has a 50-day moving average price of $25.83 and a two-hundred day moving average price of $24.82. The stock has a market capitalization of $909.47 million, a P/E ratio of -9.00 and a beta of 2.82.

Janux Therapeutics (NASDAQ:JANX – Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.21. The company had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.07 million. As a group, equities analysts predict that Janux Therapeutics will post -1.38 EPS for the current year.

Janux Therapeutics Company Profile

(Get Free Report)

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Further Reading